Journal News

Messy data, robust conclusions

Laurel Oldach
March 24, 2021

Elodie Ghedin and Christine Vogel had wanted to work together for years. They were friendly colleagues at New York University, both running interdisciplinary labs: Ghedin's focused on genomics and Vogel's on proteomics.

Vogel-Christine-445x366.jpg
Christine Vogel pipetted samples for proteomic analysis the day before her daughter's
birth in 2020.

The opportunity to collaborate arose in 2016 with what Vogel playfully recalled as "a call from the NIH saying, 'Elodie, can you help us fix Zika?'"

Program officers at the National Institutes of Health had $152 million in emergency funding to learn more about the emerging virus as quickly as possible. They called on Ghedin and others with experience in viruses and in neglected tropical diseases.

At the time, one clinical challenge was differentiating between infections with Zika and related viruses, including the deadlier dengue and chikungunya, when both were circulating. Polymerase chain reaction, or PCR, diagnostics can differentiate the two viruses but only early in infection. If a patient suffers through a few days of fever and aches before arriving at the hospital, it may be too late to detect viral RNA. Because the viruses are so similar, antibody tests often used later in disease tend to be inconclusive.

During outbreaks of both Zika and dengue in 2016 and 2017, doctors at the University of the West Indies in Trinidad did their best to diagnose patients based on ambiguous lab tests and secondary Zika symptoms such as vomiting and intense pain behind the eyes. They also started a clinical trial, collecting serum samples from over 60 patients.

"We were lucky we even got access to these samples," Ghedin said; competition among researchers was intense.

The data set was challenging to work with. There was no healthy control group, and some records were missing information about symptoms; one even lacked the participant's gender. Although the researchers had planned parallel transcriptome and proteome analyses, they had to scrap the transcriptomics, because the samples' RNA had degraded somewhere between the clinic in the Caribbean and their freezers in New York.

Mosquito-445x269.jpg
The closely related viruses that cause Zika and dengue both are transmitted by mosquitoes.

After proteomic analysis and rigorous statistical filtering, the two teams identified 13 proteins with different abundance between Zika and dengue infections, as they wrote recently in the journal Molecular & Cellular Proteomics. The differences, although small, could give new insights into Zika disease biology. For example, Ghedin said, they were surprised to observe that most proteins upregulated in Zika compared to dengue patients also are linked to pregnancy — which may yield new hypotheses about how the virus causes pregnancy complications and long-term health problems for newborns. The researchers emphasized that more validation work needs to be done before their observations can be used in the clinic.

Although urgency about understanding Zika ebbed with the epidemic, Vogel and Ghedin, who now works at the National Institute for Allergy and Infectious Diseases, continue to collaborate on multiomics studies. While studying samples from COVID-19 patients, Vogel has relied on lessons she learned from the Zika study.

"In the early days (of an outbreak), you do not have controlled studies. You just have whatever samples you can get," she said.

"I find a lot of my research is like that," Ghedin added. "You do what you can with the samples you can actually lay your hands on."

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Laurel Oldach

Laurel Oldach is a former science writer for the ASBMB.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

What’s in a diagnosis?
Essay

What’s in a diagnosis?

Sept. 4, 2025

When Jessica Foglio’s son Ben was first diagnosed with cerebral palsy, the label didn’t feel right. Whole exome sequencing revealed a rare disorder called Salla disease. Now Jessica is building community and driving research for answers.

Peer through a window to the future of science
Annual Meeting

Peer through a window to the future of science

Sept. 3, 2025

Aaron Hoskins of the University of Wisconsin–Madison and Sandra Gabelli of Merck, co-chairs of the 2026 ASBMB annual meeting, to be held March 7–10, explain how this gathering will inspire new ideas and drive progress in molecular life sciences.

Glow-based assay sheds light on disease-causing mutations
Journal News

Glow-based assay sheds light on disease-causing mutations

Sept. 2, 2025

University of Michigan researchers create a way to screen protein structure changes caused by mutations that may lead to new rare disease therapeutics.

How signals shape DNA via gene regulation
Journal News

How signals shape DNA via gene regulation

Aug. 19, 2025

A new chromatin isolation technique reveals how signaling pathways reshape DNA-bound proteins, offering insight into potential targets for precision therapies. Read more about this recent MCP paper.

A game changer in cancer kinase target profiling
Journal News

A game changer in cancer kinase target profiling

Aug. 19, 2025

A new phosphonate-tagging method improves kinase inhibitor profiling, revealing off-target effects and paving the way for safer, more precise cancer therapies tailored to individual patients. Read more about this recent MCP paper.

How scientists identified a new neuromuscular disease
Feature

How scientists identified a new neuromuscular disease

Aug. 14, 2025

NIH researchers discover Morimoto–Ryu–Malicdan syndrome, after finding shared symptoms and RFC4 gene variants in nine patients, offering hope for faster diagnosis and future treatments.